

BLEXIT - best oncological outcomes from cystectomy

Poster Session 68

Monday, 27 March
12:15 - 13:45

Location: Room Munich, North Hall (Level 1)

Chairs: To be confirmed
F. Saad
P. Zehnder, Luzern (CH)

Aims and objectives of this session

This session is designed to optimise oncological outcomes.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

895

Clinical and outcome characteristics of the cancer genome atlas (TCGA) bladder cancer cohort: Is it representative?

By: Seiler R.¹, Black P.², Thalmann G.³, Stenzl A.⁴, Todenhöfer T.⁴

Institutes:¹Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, ²University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ³University of Bern, Dept. of Urology, Bern, Switzerland, ⁴University Hospital, Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

896

Does associated CIS with MIBC impact on neoadjuvant chemotherapy? Results of an International consortium

By: Vasdev N.¹, Zagar H.², Noel J.³, Suleyman N.¹, Thorpe A.⁴, Mir M.C.⁵, Ercole C.E.⁶, Zargar-Shoshtari K.⁷, Fairey A.S.⁸, Mertens L.S.⁹, Dinney C.P.¹⁰, Krabbe L.M.¹¹, Cookson M.S.¹², Jacobsen N.E.¹³, Gandhi N.M.¹⁴, Griffin J.¹⁵, Montgomery J.S.¹⁶, Yu E.Y.¹⁷, Xylinas E.¹⁸, Campain N.J.¹⁹, Veeraterpillay R.⁴, Kassouf W.²⁰, Dall'Era M.A.²¹, Seah J.A.²², Horenblas S.⁹, Sridhar S.S.²², McGrath J.S.¹⁹, Aning J.²³, Shariat S.F.²⁴, Wright J.L.¹⁷, Morgan T.M.¹⁶, Holzbeierlein J.M.¹⁵, Bivalacqua T.J.¹⁴, North S.²⁵, Barocas D.A.²⁶, Lotan Y.¹¹, Garcia J.A.², Grivas P.², Shah J.B.¹⁰, Van Rhijn B.W.⁹, Daneshmand S.⁸, Spiess P.E.⁷, Li J.², Stephenson A.J.², Black P.⁵

Institutes:¹Lister Hospital Stevenage, Division of Robotic Urology, Department of Urology, Stevenage, United Kingdom, ²Glickman Urological and Kidney Institute and Taussig Cancer Center, Cleveland Clinic, Cleveland, United States of America, ³Division of Robotic Surgery, Dept. of Urology, Stevenage, United Kingdom, ⁴Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ⁵University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁶Cleveland Clinic, Glickman Urological and Kidney Institute and Taussig Cancer Center, Cleveland, United States of America, ⁷H. Lee Moffitt Cancer Center and Research Institute, Dept. of Genitourinary Oncology, Tampa, United States of America, ⁸University of Southern California, USC/Norris Comprehensive Cancer Center, Institute of Urology, Los Angeles, United States of America, ⁹The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ¹⁰MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ¹¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ¹²University of Oklahoma College of Medicine, Dept. of Urology, Oklahoma City, United States of America, ¹³University of Alberta, Edmonton, Alberta, Canada, ¹⁴The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Dept. of Urology, Baltimore, United States of America, ¹⁵University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America, ¹⁶University of Michigan Health System, Dept. of Urology, Ann Arbor, United States of America, ¹⁷Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research, Dept. of Medicine, Seattle, United States of America, ¹⁸Weill Cornell Medical College, Presbyterian Hospital, Dept. of Urology, New York, United States of America, ¹⁹Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Dept. of Surgery, Exeter, United Kingdom, ²⁰McGill University Health Center, Dept. of

Surgery (Division of Urology), Montreal, Canada, ²¹University of California at Davis, Davis Medical Center, Dept. of Urology, Sacramento, United States of America, ²²Princess Margaret Cancer Center, Dept. of Urology, Toronto, Canada, ²³Freeman Hospital, Dept. of Urology, New Castle upon Tyne, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Dept. of Surgery, Exeter, United Kingdom, ²⁴Weill Cornell Medical College, Presbyterian Hospital, New York, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria, ²⁵Cross Cancer Institute, Edmonton, Alberta, Canada, ²⁶Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, United States of America

- 897 **Bladder-sparing protocol consisting of low-dose chemoradiotherapy and consolidative partial cystectomy against muscle-invasive bladder cancer: A comparison of oncological outcomes between primary and progressive diseases**
By: Nakamura Y., Tanaka H., Fujii Y., Inoue M., Ito M., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Kihara K.
Institutes: Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan
- 898 **The B4GALT1 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with muscle-invasive bladder cancer**
By: Xie H.¹, Zhou L.², Zhu Y.¹, Wang Z.³, Fu Q.³, Zhu Y.¹, Shen Y.¹, Xu J.³, Ye D.¹
Institutes:¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China, ³School of Basic Medical Sciences, Fudan University, Biochemistry and Molecular Biology, Shanghai, China
- 899 **Pattern of positive node metastases in patients treated with extended and super extended pelvic lymph node dissection and radical cystectomy due to bladder cancer**
By: Moschini M.¹, Colombo R.¹, Suardi N.⁴, Burgio G.¹, Bandini M.¹, Zaffuto E.¹, Damiano R.², Mattei A.³, Shariat S.⁴, Briganti A.¹, Montorsi F.¹, Gallina A.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ³Klinik Für Urologie, Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria
- 900 **Circulating tumor cells do not correspond with clinicopathological characteristics of muscle-invasive bladder cancer patients undergoing radical cystectomy: Interim results of the CirGuidance study**
By: Boormans J.L.¹, De Kruijff I.², Beije N.², Kraan J.³, Te Slaa E.⁴, Wijburg C.⁵, Van Der Hoeven J.⁶, Van Der Heijden A.G.⁷, Somford R.⁸, Klaver O.S.⁹, Van N.M.³, Martens J.W.³, Sleijfer S.²
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Medical Oncology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Medical Oncology and Cancer Genomics, Rotterdam, The Netherlands, ⁴Isala Klinieken, Dept. of Urology, Zwolle, The Netherlands, ⁵Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands, ⁶RDGG, Dept. of Urology, Delft, The Netherlands, ⁷Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ⁸CWZ, Dept. of Urology, Nijmegen, The Netherlands, ⁹Maastadziekenhuis, Dept. of Urology, Rotterdam, The Netherlands
- 901 **Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy**
By: Seiler R.¹, Ashab H.A.D.², Erho N.², Van Rhijn B.W.³, Winters B.⁴, Douglas J.⁵, Van Kessel K.⁶, Fransen Van De Putte E.³, Sommerlad M.⁵, Wang Q.⁷, Choerung V.⁷, Gibb E.⁷, Palmer-Aronsten B.⁷, Lam L.⁷, Buerki C.⁷, Davicioni E.⁷, Sjö Dahl G.⁸, Kardos J.⁹, Hoadley K.⁹, Lerner S.¹⁰, McConkey D.¹¹, Choi W.¹¹, Kim W.⁹, Kiss B.¹², Thalmann G.¹², Todenhöfer T.¹³, Crabb S.¹⁴, North S.¹⁵, Zwarthoff E.⁶, Boormans J.⁶, Wright J.⁴, Dall'Era M.¹⁶, Van Der Heijden M.³, Black P.¹³
Institutes:¹Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, ²GenomeDx, Biosciences, Vancouver, Canada, ³Netherlands Cancer Institute, Dept. of Surgical Oncology, Division of Urology, Amsterdam, The Netherlands, ⁴University of Washington School of Medicine, Dept. of Urology, Seattle, United States of America, ⁵University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, ⁶Erasmus MC, University Medical Center Rotterdam, Dept. of Pathology, Rotterdam, The Netherlands, ⁷GenomeDx, Dept. of Biosciences, Vancouver, Canada, ⁸Department of Translational Medicine, Lund University, Division of Urological Research, Malmö, Sweden, ⁹University of North Carolina At Chapel Hill, Lineberger Comprehensive Cancer Center,

Chapel Hill, United States of America, ¹⁰Baylor College of Medicine, Dept. of Urologic Oncology, Houston, United States of America, ¹¹University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ¹²University of Bern, Dept. of Urology, Bern, Switzerland, ¹³University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ¹⁴University Hospital of Southampton, Dept. of Medical Oncology, Hampshire, United Kingdom, ¹⁵University of Alberta Edmonton, Cross Care Institute, Dept. of Oncology, Alberta, Canada, ¹⁶University of Sacramento, UC Davis Comprehensive Cancer Center, Sacramento, United States of America

- 902 **Preoperative double-J stenting increases the risk of upper urinary tract (UUT) recurrence after radical cystectomy**
By: Kiss B.¹, Furrer M-A.¹, Wuethrich P.², Burkhard F.¹, Thalmann G.¹, Roth B.¹
Institutes:¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²University Hospital Bern, Dept. of Anesthesiology, Bern, Switzerland
- 903 **Impact of perioperative transfusion of red blood cells and fresh frozen plasma on recurrence-free survival of patients after radical cystectomy for bladder cancer**
By: Schubert T., Schmid M.A., Renninger M., Lütfnrenk T., Stenzl A., Gakis G.
Institutes:University Hospital of Tübingen, Dept. of Urology, Tübingen, Germany
- 904 **Fate of patients undergoing pulmonary metastasectomy for metastatic urothelial carcinoma**
By: Hoshi S.¹, Fukui I.², Kageyama Y.³, Kawashima K.⁴, Narita S.⁵, Ono K.⁶, Numahata K.¹, Sato M.⁸, Morozumi K.⁸, Kuromoto A.⁸, Ozawa M.⁸, Hoshi K.⁷, Bilim V.⁷, Sasagawa I.⁷
Institutes:¹Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan, ²Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, ³Saitama Prefectural Cancer Center, Dept. of Urology, Saitama, Japan, ⁴Tochige Prefectural Cancer Center, Dept. of Urology, Tochigi, Japan, ⁵Akita University Hospital, Dept. of Urology, Akita, Japan, ⁶Ishinomaki Redcross Hospital, Dept. of Urology, Ishinomaki, Japan, ⁷Yamagata Tokushukai Hospital, Dept. of Urology, Yamagata, Japan, ⁸Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan
- 905 **Characterization of genomic aberrations of circulating, cell-free DNA in bladder cancer patients treated with radical cystectomy using multiplex ligation-dependent probe amplification: A new and efficient profiling method**
By: Soave A.¹, Chun F.¹, Rink M.¹, Weisbach L.¹, Maurer V.¹, Gild P.¹, Steinbach B.², Fisch M.¹, Pantel K.², Schwarzenbach H.²
Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Dept. of Tumor Biology, Hamburg, Germany
- 906 **Perioperative allogeneic blood transfusion does not adversely impact survival after radical cystectomy for urinary bladder cancer – a competing-risks analysis from a multi-institutional European series**
By: Gild P.¹, Vetterlein M.¹, Kluth L.A.¹, Gierth M.², Fritsche H-M.², Burger M.², Protzel C.³, Hakenberg O.³, Von Landenberg N.⁴, Roghmann F.⁴, Noldus J.⁴, Nuhn P.⁵, Rink M.¹, Chun F.¹, May M.⁶, Fisch M.¹, Aziz A.¹
Institutes:¹Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ³University of Rostock, Dept. of Urology, Rostock, Germany, ⁴Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ⁵University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ⁶St. Elisabeth Medical Center Straubing, Dept. of Urology, Straubing, Germany
- 907 **A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic**
By: Kulkarni G.¹, Hermanns T.¹, Wei Y.¹, Bhindi B.¹, Satkunasingam R.¹, Athanasopoulos P.¹, Bostrom P.¹, Kuk C.², Li K.¹, Templeton A.³, Sridhar S.³, Van Der Kwast T.⁴, Chung P.⁵, Bristow R.⁵, Milosevic M.⁵, Warde P.⁵, Fleshner N.⁶, Jewett M.⁶, Bashir S.⁷, Zlotta A.⁸
Institutes:¹Princess Margaret Cancer Centre, University Health Network, Dept. of Surgery, Toronto, Canada, ²Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada, ³Princess Margaret Cancer

Centre, University Health Network, Dept. of Medical Oncology, Toronto, Canada, ⁴Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, ⁵Princess Margaret Hospital, University Health Network, Radiation Medicine Program, Toronto, Canada, ⁶Princess Margaret Cancer Centre, University Health Network, Dept. of Surgery (urology), Toronto, Canada, ⁷Princess Margaret Cancer Centre, University Health Network, Dept. of Biostatistics, Toronto, Canada, ⁸Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada

908

Outcome of patients undergoing radical cystectomy for urothelial cell carcinoma of the bladder with evidence of distant metastases. Results of a single center study

By: Grimm T., Buchner A., Schneevoigt B-S., Kretschmer A., Grabbert M., Jokisch F., Schulz G., Stief C.G., Karl A.

Institutes:LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany

909

The accuracy of sequential urethral frozen sections and its impact on urethral recurrence after radical cystectomy

By: Schubert T., Schmid M.A., Renninger M., Lütfnik T., Stenzl A., Gakis G.

Institutes:University Hospital of Tübingen, Dept. of Urology, Tübingen, Germany